# Bioequivalence Study for Acarbose/Metformin FDC

> **NCT04065581** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Acarbose/Metformin FDC(BAY81-9783)
- **DRUG:** Glucobay
- **DRUG:** Glucophage

## Key facts

- **NCT ID:** NCT04065581
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2019-11-25
- **Final completion:** 2020-03-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065581, "Bioequivalence Study for Acarbose/Metformin FDC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04065581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*